PROTHENA CORP PUBLIC LTD CO
Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.
Prothena (NASDAQ:PRTA) reported Q2 2026 results and business updates. Quarter-end cash and restricted cash were $289.1M, with updated 2026 cash guidance to about $259M (midpoint). Q2 net loss was $18.6M. The company cited Roche Phase 2b PADOVA prasinezumab data in The Lancet and ongoing Phase 3 and other partner trials.
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide
Over the past 7 days, alphai's AI scored 3 news stories mentioning PRTA (PROTHENA CORP PUBLIC LTD CO). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent PRTA coverage spans insider activity and earnings.
In the last 30 days, PRTA insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($2.9M). The most active reporter was Kingston Anne Evans, Chief Strategy Officer, with 1 filing. 25% of activity was filed under pre-arranged Rule 10b5-1 plans.
Results and cash guidance reaffirmation reduce near-term funding risk, while pipeline milestones tied to BMY/Roche/Novo Nordisk shape optionality.
Cash guidance update plus new partner clinical readout (Roche Phase 2b PADOVA) can shift expectations for partnered milestone/royalty timing.
Updated cash guidance and partner clinical readouts (Roche Phase 2b PADOVA) reinforce near-term funding runway and de-risk partnered assets, supporting sentiment but not a standalone valuation reset.
This is a routine Form 4 insider transaction with no stated 10b5-1 plan, but it is not a fundamental company catalyst by itself.
This is a routine insider transaction with no stated operational or financial catalyst for PRTA.
alphai scores every news story that mentions PRTA with an AI model for sentiment and relevance, and aggregates insider trades from PROTHENA CORP PUBLIC LTD CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.
7 min readProthena (NASDAQ:PRTA) reported Q2 2026 results and business updates. Quarter-end cash and restricted cash were $289.1M, with updated 2026 cash guidance to about $259M (midpoint). Q2 net loss was $18.6M. The company cited Roche Phase 2b PADOVA prasinezumab data in The Lancet and ongoing Phase 3 and other partner trials.
6 min readPROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide
6 min readZago Wagner M. (Chief Scientific Officer) sold (to issuer) 51,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.44M total) on 2026-07-28.
2 min readWalker Karin L (Chief Accounting Officer) sold (to issuer) 15,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.13M total) on 2026-07-28.
2 min readSwanson Chad J. (Chief Development Officer) sold (to issuer) 40,800 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.35M total) on 2026-07-28.
2 min readSmith Brandon S. (Chief Operating Officer) sold (to issuer) 78,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.67M total) on 2026-07-28.
1 min readNguyen Tran (Chief Strategy Officer and CFO) sold (to issuer) 57,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.49M total) on 2026-07-28.
2 min readKinney Gene G. (President and CEO) sold (to issuer) 84,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $8.56 ($0.72M total) on 2026-07-28.
1 min readProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the close of the U.S. financial markets.
1 min read
